(Q2)Jul 31, 2024 | (Q1)Apr 30, 2024 | (FY)Jan 31, 2024 | (Q4)Jan 31, 2024 | (Q3)Oct 31, 2023 | (Q2)Jul 31, 2023 | (Q1)Apr 30, 2023 | (FY)Jan 31, 2023 | (Q4)Jan 31, 2023 | (Q3)Oct 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow (Indirect Method) | ||||||||||
Cash flow from continuing operating activities | -112.21%-115.55K | 20.74%-24.79K | -9.24%-229.06K | -48.09%-87.95K | -138.72%-55.39K | 57.12%-54.45K | -23,773.28%-31.27K | -4,310.81%-209.69K | -59.39K | -23.2K |
Net income from continuing operations | -922.57%-125.94K | 56.77%-15.07K | -54.63%-280.13K | -276.96%-169.19K | -2,494.30%-63.77K | 90.86%-12.32K | -4,129.83%-34.86K | -1,740.02%-181.16K | ---44.88K | ---2.46K |
Operating gains losses | ---- | ---- | ---1.2K | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
Other non cashItems | -1.89%3.02K | 484.10%3.99K | 170.96%2.94K | -721.49%-8.72K | 1,006.12%9.62K | 398.54%3.08K | -4.22%-1.04K | -5,219.23%-4.15K | ---1.06K | ---1.06K |
Change In working capital | 110.43%4.72K | -396.52%-13.71K | 302.29%49.33K | 777.93%91.16K | 93.69%-1.24K | -617.03%-45.21K | --4.62K | -55.09%-24.38K | ---13.45K | ---19.68K |
-Change in receivables | 1,696.39%10.62K | 95.58%-74 | -47.28%-12.47K | -186.78%-7.01K | -19,406.25%-3.12K | 88.93%-665 | ---1.67K | -846,300.00%-8.46K | ---2.44K | ---16 |
-Change in prepaid assets | --0 | --0 | 451.03%40.86K | 821.03%76.99K | --0 | ---40.2K | --4.07K | 48.26%-11.64K | --8.36K | ---20K |
-Change in payables and accrued expense | -35.80%-5.9K | -713.46%-13.63K | 589.11%20.93K | 209.35%21.17K | 462.57%1.88K | -129.45%-4.34K | --2.22K | -163.12%-4.28K | ---19.36K | --334 |
Cash from discontinued investing activities | ||||||||||
Operating cash flow | -112.21%-115.55K | 20.74%-24.79K | -9.24%-229.06K | -48.09%-87.95K | -138.72%-55.39K | 57.12%-54.45K | -23,773.28%-31.27K | -4,310.81%-209.69K | ---59.39K | ---23.2K |
Investing cash flow | ||||||||||
Cash flow from continuing investing activities | -481.77%-130K | 0 | 0.00%-50K | -13.51%-34.05K | 0 | 34.05K | -50K | -66.67%-50K | -30K | -20K |
Net PPE purchase and sale | ---130K | --0 | 0.00%-50K | --0 | --0 | --0 | ---50K | ---50K | --0 | ---50K |
Net other investing changes | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- | ---- |
Cash from discontinued investing activities | ||||||||||
Investing cash flow | -481.77%-130K | --0 | 0.00%-50K | -13.51%-34.05K | --0 | --34.05K | ---50K | -66.67%-50K | ---30K | ---20K |
Financing cash flow | ||||||||||
Cash flow from continuing financing activities | 59.50%319K | 6K | 283.33%115K | -600.00%-150K | 65K | 200K | 0 | -93.35%30K | 30K | 0 |
Net issuance payments of debt | -128.00%-56K | --6K | --115K | ---150K | --65K | --200K | --0 | --0 | --0 | --0 |
Net common stock issuance | ---- | ---- | --0 | ---- | ---- | ---- | ---- | -93.35%30K | ---- | ---- |
Cash from discontinued financing activities | ||||||||||
Financing cash flow | 59.50%319K | --6K | 283.33%115K | -600.00%-150K | --65K | --200K | --0 | -93.35%30K | --30K | --0 |
Net cash flow | ||||||||||
Beginning cash position | -96.49%3.7K | -87.95%22.48K | -55.18%186.54K | 19.74%294.48K | -1.47%284.87K | -74.70%105.27K | -55.18%186.54K | --416.23K | --245.93K | --289.13K |
Current changes in cash | -59.10%73.45K | 76.88%-18.79K | 28.57%-164.06K | -358.00%-272K | 122.25%9.61K | 241.45%179.6K | -61,941.22%-81.27K | -155.18%-229.69K | ---59.39K | ---43.2K |
End cash Position | -72.92%77.15K | -96.49%3.7K | -87.95%22.48K | -87.95%22.48K | 19.74%294.48K | -1.47%284.87K | -74.70%105.27K | -55.18%186.54K | --186.54K | --245.93K |
Free cash from | -350.96%-245.55K | 69.50%-24.79K | -7.46%-279.06K | -48.09%-87.95K | 24.34%-55.39K | 57.12%-54.45K | -61,941.22%-81.27K | -5,362.56%-259.69K | ---59.39K | ---73.2K |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.
No Data